Newly-launched ULB oncology spinout Epics Therapeutics will aim to develop drugs targeting malignant epigenetic RNA modifications.

Wanxiang-backed OM1 has raised series B funding that will be used to enhance its medical data analysis platform.

Oxford Sciences Innovation has led a $13.4m series A round for Ultromics, an Oxford spinout working on technology to diagnose coronary heart disease.

Merck and ENGC are in line for exits after Electrocore, the developer of a nerve stimulation treatment for headaches, filed to raise up to $74.8m.

Naspers Ventures led the senior care provider's latest round, investing alongside unnamed existing backers to increase its total funding to $115m.

Existing investors GE Ventures and Humana both took part as the primary healthcare provider boosted its overall funding to more than $220m.